The GLP-1 Challenge: Addressing Discontinuation Rates and Muscle Loss

The rise of glucagon-like peptide-1 receptor agonists (GLP-1s) like Ozempic and Wegovy has revolutionized the treatment of obesity and diabetes. However, alongside their success, significant challenges are emerging, particularly concerning high discontinuation rates and potential muscle loss. While these medications offer substantial health benefits, ensuring long-term adherence and mitigating side effects are crucial for maximizing their impact.

High Discontinuation Rates: A Growing Concern

Despite the increasing popularity of GLP-1s – with approximately 12% of U.S. Adults having tried them as of June 2024 – a substantial number of patients stop using these medications within the first year. Studies indicate that between 50% and 75% of individuals discontinue GLP-1 therapy within 12 months. This high rate of discontinuation poses a significant barrier to sustained weight management and improved health outcomes.

Several factors contribute to this trend. The high cost of these therapies is a major obstacle for many patients. Unlike medications for chronic conditions like blood pressure or cholesterol, GLP-1s are sometimes perceived as temporary treatments, with individuals believing they can stop once they reach their weight loss goals. Some too use them cosmetically, rather than for chronic disease management.

The Issue of Muscle Loss

A growing concern among healthcare professionals is the potential for muscle loss associated with GLP-1s. While weight loss inevitably involves some muscle mass reduction, the effectiveness of these drugs for weight loss is bringing this side effect into sharper focus. Muscle strength is linked to better long-term health, yet GLP-1s, which can diminish muscle strength, have also been shown to improve health outcomes by lowering the risk of heart and kidney disease.

Currently, the clinical significance of muscle loss with GLP-1 use remains unclear. More research is needed to determine whether muscle loss leads to observable clinical consequences, such as increased falls in older adults. Functional data, including patient-reported outcomes, are essential for a comprehensive understanding of the impact of muscle loss.

Strategies for Muscle Preservation

While researchers work to understand the clinical implications of muscle loss, individuals taking GLP-1s can take proactive steps to preserve muscle mass:

• Nutrition: Prioritize Protein Intake: Adequate protein intake is fundamental for maintaining muscle mass. Recommended daily intake ranges from 0.8 to 1.5 grams of protein per kilogram of body weight. Individuals on GLP-1s, who may experience reduced appetite, may benefit from protein supplements, such as high-protein, low-fat nutrition shakes.
• Strength Training: The Cornerstone of Muscle Maintenance: Strength training, also known as resistance training, is crucial for building and preserving muscle. It directly targets muscles and increases metabolism, promoting long-term fat loss. Simple exercises using body weight (pushups, planks) or resistance bands are effective and accessible.

Research suggests that just one hour of resistance training per week can lower mortality risk by 27%, comparable to the benefits of quitting smoking or taking medication.

The Evolving Role of Fitness Professionals

There is growing recognition of the importance of integrating fitness professionals into the care team for patients using GLP-1s. Organizations like the National Exercise & Sports Trainers’ Association are now offering GLP-1 Exercise Specialist Certifications, and the National Academy of Sports Medicine provides continuing education programs on weight loss medications for fitness and wellness professionals. However, insurance coverage for fitness coaching remains limited.

Emerging Therapies and Future Research

Researchers are actively developing therapies specifically designed to preserve muscle mass alongside weight loss. Bimagrumab is one such agent currently undergoing clinical trials. The Food and Drug Administration (FDA) has also released draft guidance requiring new drug developers to include baseline and follow-up measurements of body composition using DXA scans in clinical trials, acknowledging the importance of monitoring muscle mass.

Concluding Thoughts

For healthcare providers, emphasizing the importance of muscle mass preservation, encouraging strength training, and ensuring adequate protein intake are vital components of care for patients taking GLP-1s. Digital health tools and collaboration with dietitians, certified diabetes care and education specialists, and fitness coaches can enhance support. Older adults, who are at greater risk for the consequences of muscle loss, may particularly benefit from these interventions. Addressing muscle preservation is critical to maximizing the long-term health benefits of GLP-1s and improving the quality of life for individuals with diabetes and obesity.